ProMIS Neurosciences (PMN) late Wednesday filed a shelf registration statement with US regulators for the potential sale of up to $200 million of securities, to be offered from time to time.
The filing covers common shares, preferred shares, subscription receipts, debt securities, warrants and units.
The company said it intends to use the net proceeds for the clinical development of PMN310 therapeutic candidate, for working capital and general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.